Exelixis
EXEL
$21.06
Share price
-0.31%
Change (1 day)
7.97%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Exelixis (EXEL) - Cash on Hand
Cash on Hand as of March 2024 : $0.96 B
According to Exelixis's latest financial reports the company has $0.96 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Exelixis - Cash on Hand chart (from 2001 to 2024)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $0.99 B | -23.93% |
| 2022-12-31 | $1.30 B | -10.81% |
| 2021-12-31 | $1.46 B | 21.59% |
| 2020-12-31 | $1.20 B | 41.57% |
| 2019-12-31 | $0.85 B | 22.92% |
| 2018-12-31 | $0.69 B | 78.8% |
| 2017-12-31 | $0.38 B | -7.63% |
| 2016-12-31 | $0.41 B | 151.29% |
| 2015-12-31 | $0.16 B | 15.78% |
| 2014-12-31 | $0.14 B | -40.49% |
| 2013-12-31 | $0.24 B | -41.07% |
| 2012-12-31 | $0.41 B | 111.8% |
| 2011-12-31 | $0.19 B | 19.43% |
| 2010-12-31 | $0.16 B | -19.9% |
| 2009-12-31 | $0.20 B | -22.6% |
| 2008-12-31 | $0.26 B | -3.37% |
| 2007-12-31 | $0.27 B | 51.8% |
| 2006-12-31 | $0.17 B | 20.35% |
| 2005-12-31 | $0.14 B | -4.22% |
| 2004-12-31 | $0.15 B | -34.55% |
| 2003-12-31 | $0.23 B | 6.8% |
| 2002-12-31 | $0.22 B | -2.51% |
| 2001-12-31 | $0.22 B |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $26.21 B | 2,621.81% | 🇺🇸 USA |
 Pfizer PFE | $12.69 B | 1,217.41% | 🇺🇸 USA |
 Amgen AMGN | $10.94 B | 1,036.15% | 🇺🇸 USA |
 Sanofi SNY | $9.92 B | 930.69% | 🇫🇷 France |
 Merck MRK | $7.09 B | 636.36% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $9.67 B | 903.89% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $5.17 B | 437.24% | 🇬🇧 UK |
 Curis CRIS | $56.33 M | -94.15% | 🇺🇸 USA |
 AVEO Oncology
AVEO | $77.39 M | -91.96% | 🇺🇸 USA |